Vetr upgraded shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday morning. They currently have $7.35 price target on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on the company. Zacks Investment Research cut Aurinia Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, June 27th. BidaskClub cut Aurinia Pharmaceuticals from a hold rating to a sell rating in a report on Friday, July 28th. Finally, Cantor Fitzgerald set a $14.00 price objective on Aurinia Pharmaceuticals and gave the stock a buy rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $9.79.

Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) opened at 6.22 on Tuesday. The firm has a 50-day moving average price of $6.22 and a 200-day moving average price of $6.72. Aurinia Pharmaceuticals has a 52-week low of $2.02 and a 52-week high of $10.54. The stock’s market cap is $519.28 million.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.10. The firm had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. On average, analysts anticipate that Aurinia Pharmaceuticals will post ($0.94) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Vetr Inc. Upgrades Aurinia Pharmaceuticals Inc (AUPH) to Strong-Buy” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/23/vetr-inc-upgrades-aurinia-pharmaceuticals-inc-auph-to-strong-buy.html.

Several hedge funds have recently bought and sold shares of AUPH. Royal Bank of Canada boosted its holdings in shares of Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,341 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $155,000. Cutler Capital Management LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth $184,000. Investment Centers of America Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth $184,000. Finally, Two Sigma Securities LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $240,000. Institutional investors and hedge funds own 27.78% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.